IP Verse

Aventis competitive analysis

Loading summary...

Latest oppositions filed by Aventis

Explore patent oppositions filed by Aventis against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Oct 23, 2025

Patent Number	Title	Applicant	Opposition Date
Get instant updates on new opposition filings by the company
EP3668568	Dosage Measurement Module On Injection Pen	ELI LILLY	Mar 7, 2025
EP4017557	Methods And Apparatus For Aspects Of A Dose Detection System	ELI LILLY	Nov 4, 2024
EP3706841	Needle Shield Remover And A Medicament Delivery Device Comprising The Needle Shield Remover	SHL MEDICAL	Aug 22, 2024
EP3184138	Needle Cover Assembly	SHL GROUP	Jan 12, 2024
EP3666797	Antigen Binding Proteins To Proprotein Convertase Subtilisin Kexin Type 9 (Pcsk9)	AMGEN	Nov 10, 2023
EP3740265	A Medicament Delivery Device With A Removable Cap And Locking Member For Preventing Accidental Activiation	CONSORT MEDICAL	Aug 16, 2023
EP3359229	Injector Comprising A Destructible Electric Circuit As A Result Of Use	TECPHARMA LICENSING	Feb 16, 2023
EP3071262	Rotary Sensor Assembly With Space Efficient Design	NOVO NORDISK	Dec 22, 2020
EP3265152	Data Acquisiton Means, Especially For A Pen-Type Drug Delivery Devices	BEREY	Oct 22, 2020
EP2296728	Administration Device Having A Button With Touch Sensor	F HOFFMANN LA ROCHE	Jul 30, 2020

Latest patents of Aventis opposed by its competitors

Explore Aventis's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Oct 23, 2025

Patent Number	Grant Date	Title	Total Oppositions
EP2493466	Mar 10, 2021	Novel Antitumoral Use Of Cabazitaxel	13
EP3294285	Dec 18, 2019	Cabazitaxel And Its Use For Treating Cancer	10
EP2678011	Jun 26, 2019	Antitumoral Combination Comprising Cabazitaxel And Cisplatin	1

Latest publications and patents of Aventis New

Explore the latest publications and patents granted to Aventis, showcasing their recent innovations and technological advancements.

Last updated on: Oct 18, 2025

Publication Number	Publication Date	Title	Legal Status
Get instant update for new patents of Aventis
EP2493466	Mar 10, 2021	Novel Antitumoral Use Of Cabazitaxel	Opposition Rejected
EP3294285	Dec 18, 2019	Cabazitaxel And Its Use For Treating Cancer	Revoked
EP2678011	Jun 26, 2019	Antitumoral Combination Comprising Cabazitaxel And Cisplatin	Revoked

Latest PTAB cases involving Aventis

Discover the latest PTAB cases involving Aventis, highlighting their recent legal challenges and patent disputes.

Last updated on: Oct 24, 2025

Proceeding Number	Filing Date	Petitioner	Respondent	Status
Get alerts for PTAB Cases involving Aventis
IPR2023-01045	Jun 30, 2023	NOVARTIS GENE THERAPIES	AVENTIS	Terminated-Settled
IPR2019-00136	Oct 31, 2018	NEPTUNE GENERICS	AVENTIS PHARMA	Institution Denied
IPR2016-00712	Mar 15, 2016	MYLAN LABORATORIES	AVENTIS PHARMA	Final Written Decision
IPR2016-00627	Feb 17, 2016	MYLAN LABORATORIES	AVENTIS PHARMA	Institution Denied

Peer Comparison New

IP litigation analysis comparing Aventis with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Oct 23, 2025

Company	Oppositions Filed	Oppositions Faced	PTAB Cases Filed	PTAB Cases Faced
SANOFI AVENTIS DEUTSCHLAND	16	30	-	24
MYLAN PHARMACEUTICALS	-	-	94	-
PFIZER	51	87	43	12
YPSOMED	18	14	-	-